Groupama Asset Managment Takes Position in Qiagen N.V. $QGEN

Groupama Asset Managment purchased a new position in Qiagen N.V. (NYSE:QGEN) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 12,500 shares of the company’s stock, valued at approximately $500,000.

Other institutional investors also recently added to or reduced their stakes in the company. Massachusetts Financial Services Co. MA raised its position in Qiagen by 1.1% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 24,205,881 shares of the company’s stock worth $1,088,538,000 after acquiring an additional 264,921 shares during the period. Vanguard Group Inc. grew its position in shares of Qiagen by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 9,542,944 shares of the company’s stock valued at $433,871,000 after acquiring an additional 118,135 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Qiagen by 12.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 8,429,424 shares of the company’s stock valued at $379,072,000 after acquiring an additional 906,589 shares during the period. Deutsche Bank AG increased its stake in shares of Qiagen by 9.7% during the 4th quarter. Deutsche Bank AG now owns 7,907,801 shares of the company’s stock worth $355,614,000 after purchasing an additional 697,342 shares during the last quarter. Finally, Amundi increased its stake in shares of Qiagen by 12.4% during the 1st quarter. Amundi now owns 4,757,681 shares of the company’s stock worth $190,498,000 after purchasing an additional 524,959 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Analysts Set New Price Targets

QGEN has been the subject of several research reports. Barclays set a $38.00 price objective on Qiagen and gave the company an “equal weight” rating in a report on Wednesday, April 29th. Kepler Capital Markets set a $38.60 price target on Qiagen and gave the company a “hold” rating in a research report on Thursday, June 25th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a $43.00 price target on shares of Qiagen in a research note on Thursday, April 30th. Morgan Stanley raised Qiagen from an “overweight” rating to an “overweight” rating and lifted their price objective for the stock from $40.00 to $42.00 in a report on Tuesday, June 23rd. Finally, Berenberg Bank set a $45.50 price objective on shares of Qiagen and gave the company a “hold” rating in a report on Tuesday, July 14th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $43.34.

Qiagen Trading Up 0.4%

Shares of QGEN stock opened at $41.56 on Monday. The stock has a market capitalization of $8.56 billion, a price-to-earnings ratio of 21.70, a PEG ratio of 4.13 and a beta of 0.64. The company’s fifty day simple moving average is $38.82 and its two-hundred day simple moving average is $41.84. Qiagen N.V. has a 1 year low of $32.53 and a 1 year high of $57.81. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.21 and a quick ratio of 2.57.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.54 EPS for the quarter, hitting analysts’ consensus estimates of $0.54. The firm had revenue of $492.32 million during the quarter, compared to analyst estimates of $496.15 million. Qiagen had a return on equity of 14.40% and a net margin of 19.16%.During the same period last year, the company earned $0.56 earnings per share. As a group, analysts anticipate that Qiagen N.V. will post 2.43 earnings per share for the current year.

Qiagen Increases Dividend

The business also recently declared an annual dividend, which was paid on Tuesday, July 14th. Stockholders of record on Tuesday, July 7th were given a dividend of $0.35 per share. This is a boost from Qiagen’s previous annual dividend of $0.26. This represents a dividend yield of 90.0%. The ex-dividend date was Tuesday, July 7th. Qiagen’s dividend payout ratio (DPR) is currently 18.32%.

About Qiagen

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.